Hypomethylating agents (HMA)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Hypomethylating agents (HMA), covering 2025-04-22 to 2025-04-22. Get the full timeline:
Most recent: Clinical Trial Update: Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction [Phase 2]